comparemela.com

Milan Writing News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ECB will have key data by June to decide on first rate cut

ECB will have key data by June to decide on first rate cut
zawya.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from zawya.com Daily Mail and Mail on Sunday newspapers.

ECB will have key data by June to decide on first rate cut - Lane

The European Central Bank will have key data by June to decide on the first of a likely series of interest rate cuts but going too fast may prove self-defeating, ECB chief economist Philip Lane said. -January 13, 2024 at 12:24 pm EST - MarketScreener

Nervous staff and no bankers: Western firms struggle to exit Russia | Hellenic Shipping News Worldwide

For foreign companies still working out what to do with their stranded Russian assets, President Vladimir Putin’s seizure of a major oil and gas project is a powerful warning: Move fast or else. Companies have been wrestling with how to exit in ways that limit the financial impact, do not put employees at risk and, .

Israel demands apology after Lavrov says Hitler had Jewish roots

Israel denounced Russian Foreign Minister Sergei Lavrov on Monday for suggesting that the Nazi leader Adolf Hitler had Jewish origins, saying his comments were anti-Semitic and dangerous.

UPDATE 3-European regulator gives green light for Astra-Oxford COVID-19 vaccine

Ludwig Burger, Pushkala Aripaka (Adds comments from news conference, reaction) Jan 29 (Reuters) - Europe’s medicines regulator on Friday approved AstraZeneca and Oxford University’s COVID-19 vaccine for people over the age of 18, the third vaccine to be cleared for use in the European Union. The AstraZeneca vaccine demonstrated an efficacy of around 60% in the trials on which the decision was based, the European Medicines Agency (EMA) said in a statement bit.ly/3pwGYlx. That is well below the level of protection shown by authorised vaccines from Pfizer and its German partner BioNTech and rival Moderna, which were around 95% effective in preventing symptomatic illness in pivotal trials.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.